Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.

Bin Su et al.PubMed ↗Publisher ↗

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with lower adverse events & safety

−62%−83% to −13%

Bigger than 9 in 10 for adverse events & safety

As reported

OR 0.38, 95% CI 0.17–0.87

Correlation, not cause

Went with higher adverse events & safety

2.1×1× to 4.2×

Bigger than 8 in 10 for adverse events & safety

As reported

OR 2.09, 95% CI 1.03–4.21

Two numbers in the abstract

the abstract, start to end

… risk of incident bone fractures (MH-OR=0.38, 95% CI 0.17-0.87); however, exenatide treatment was associated with an elevated risk of incident bone fractures (MH-OR=2.09, 95% CI 1.03-4.21).

← favours treatmentfavours comparator →

could be chance

Adverse events & safety

OR 0.380.17–0.87

Adverse events & safety

OR 2.091.03–4.21

GLP-1 receptor agonistsAdverse events & safety

1 / 3

98 papers cite itlatest 60 shown

2015

…

2017

2019

2020

2021

2022

2023

2024

2025

2026

this paperpooled ittrialcites it

The trial

NCT02473809phase 460 enrolled2015